BRCA1 and ovarian carcinoma: To further explore the potential function of DNA-PK-i in cancer treatment, we treated BRCA1-deficient UWB1 ovarian cancer cells with combination of low dose DNA-PK-i (M3814) with Pol I-i (BMH-21).